Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.40 |
| ▸ | GCK | P35557 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24445684 | 0.86 | HCAR2 (0.41) | HCAR2HCAR3GCKKDM4EALDH1A1 | |
| SCHEMBL19105598 | 0.84 | HPGDS (0.41) | LMNAVNN1PANK3 | |
| SCHEMBL22040909 | 0.81 | PDE9A (0.36) | GCKKDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL25138292 | 0.81 | HDAC6 (0.50) | — | |
| SCHEMBL21452962 | 0.81 | HCAR3 (0.38) | HCAR2HCAR3GCKMAPK1VNN1 | |
| SCHEMBL16248203 | 0.80 | KDM4E (0.42) | HCAR2HCAR3KDM4EALDH1A1ALOX15 | |
| SCHEMBL19706324 | 0.80 | HCAR2 (0.44) | HCAR2HCAR3KDM4EALDH1A1ALOX15 | |
| SCHEMBL19698929 | 0.79 | EGLN1 (0.43) | KDM4EALDH1A1 | |
| SCHEMBL21139099 | 0.79 | PANK3 (0.32) | PANK3 | |
| SCHEMBL12763742 | 0.79 | HCAR2 (0.43) | HCAR2HCAR3KDM4EALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-06-30 | — | — | US | disclosed |
| EP-3730487-B1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | GILEAD SCIENCES INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACUETICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3730487-A1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | Gilead Sciences, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10774054-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190248777-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10329286-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017218337-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248777-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, SLC10A1, FXR1 | HCAR2 87/4885HCAR3 91/4885GCK 1166/4885 |
| US-10329286-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | HCAR2 182/4885HCAR3 237/4885GCK 1257/4885 |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | HCAR2 182/4885HCAR3 237/4885GCK 1257/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | HCAR2 182/4885HCAR3 237/4885GCK 1257/4885 |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | HCAR2 182/4885HCAR3 237/4885GCK 1257/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | HCAR2 378/4885HCAR3 1217/4885GCK 3176/4885 |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | HCAR2 182/4885HCAR3 237/4885GCK 1257/4885 |
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, SLC10A1, FXR1 | HCAR2 87/4885HCAR3 91/4885GCK 1166/4885 |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, SLC10A2 | HCAR2 92/4885HCAR3 103/4885GCK 1203/4885 |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | HCAR2 182/4885HCAR3 237/4885GCK 1257/4885 |
| US-10774054-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | HCAR2 182/4885HCAR3 237/4885GCK 1257/4885 |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | HCAR2 182/4885HCAR3 237/4885GCK 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.